Association of adverse cardiovascular events with gabapentin and pregabalin among patients with fibromyalgia
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0307515 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Yiheng Pan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Computer and Data Science Department, Case Western Reserve University Case School of Engineering, Cleveland, OH, United States of America. Hauptthemen laut MEDLINE: Fibromyalgia, Pregabalin, Gabapentin, Cardiovascular Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, National Institute on Alcohol Abuse and Alcoholism, National Institute on Aging.
Abstract (Originalsprache)
Objective
Fibromyalgia, a chronic pain disorder, impacts approximately 2% of adults in the US. Gabapentin and pregabalin are common treatments to manage fibromyalgia-related pain. Our recent study showed the risk of adverse cardiovascular events increased in diabetic neuropathy patients who were prescribed gabapentin or pregabalin. Here, we investigated whether the prescription of gabapentin or pregabalin has similar cardiovascular risk in patients with fibromyalgia.
Methods
This retrospective cohort study leveraged electronic health records from 64 US healthcare organizations with 112 million patients. The study population included 105,602 patients first diagnosed with fibromyalgia and followed by a prescription of gabapentin, pregabalin, or other FDA-approved drugs for treating fibromyalgia from 2010 to 2019. Outcomes were deep venous thrombosis (DVT), myocardial infarcts (MI), peripheral vascular disease (PVD), strokes, heart failure, and pulmonary embolism (PE). In propensity-score-matched cohorts, 1-year and 5-year hazard ratios (HRs) were computed with their respective 95% confidence intervals (CIs). Additionally, we conducted sensitivity analyses on the subpopulations without other possible indications.
Results
For 5-year follow-up, gabapentin increased the risk of PVD (HR = 1.46, 95% CI = 1.17–1.80), MI (HR = 1.31, 95% CI = 1.03–1.66), heart failure (HR = 1.27, 95% CI = 1.10–1.48), DVT (HR = 1.80, 95% CI = 1.33–2.44), and PE (HR = 2.23, 95% CI = 1.62–3.07). Pregabalin increased the risk of DVT (HR = 1.49, 95% CI = 1.01–2.20), and PE (HR = 2.24, 95% CI = 1.43–3.50). For 1-year follow-up, gabapentin increased the risk of PVD (HR = 1.32, 95% CI = 1.11–1.57), DVT (HR = 1.35, 95% CI = 1.09–1.68), and PE (HR = 1.36, 95% CI = 1.17–1.57). Pregabalin increased the risk of PVD (HR = 1.32, 95% CI = 1.06–1.63) and PE (HR = 1.25, 95% CI = 1.03–1.52). Sensitivity analyses showed similar trends.
Conclusion
In fibromyalgia patients, the prescription of gabapentin and pregabalin moderately increased the risk of several adverse cardiovascular events. This risk, together with benefits and other adverse reactions, should be considered when prescribing these medications for fibromyalgia patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Computer and Data Science Department, Case Western Reserve University Case School of Engineering, Cleveland, OH, United States of America.
- Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.
- Department of Family Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.
- The Center for Clinical Informatics Research and Education, The Metro Health System, Cleveland, OH, United States of America.
ORCID-Profile: Yiheng Pan
Förderung
- NCATS NIH HHS
- National Institute on Alcohol Abuse and Alcoholism
- National Institute on Aging
- National Cancer Institute Case Comprehensive Cancer Center
- National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health
Zitieren
APA
Pan, Y., Blankfield, R. P., Kaelber, D. C., & Xu, R. (2024). Association of adverse cardiovascular events with gabapentin and pregabalin among patients with fibromyalgia. PLOS ONE. https://doi.org/10.1371/journal.pone.0307515
Vancouver
Pan Y, Blankfield RP, Kaelber DC, Xu R. Association of adverse cardiovascular events with gabapentin and pregabalin among patients with fibromyalgia. PLOS ONE. 2024. doi:10.1371/journal.pone.0307515
BibTeX
@article{Pan2024,
author = {Pan, Yiheng and Blankfield, Robert P and Kaelber, David C and Xu, Rong},
title = {Association of adverse cardiovascular events with gabapentin and pregabalin among patients with fibromyalgia},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0307515}
}
EUVIMED